Chrysalis BioTherapeutics
Chrysalis BioTherapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing regenerative drugs that utilize natural processes to activate endothelial and stem cells, aiming to accelerate tissue repair and improve lives. The company focuses on treatments for serious respiratory disorders, radiation exposure, diabetic foot ulcers, and related medical conditions, with a mission to help improve people's lives through innovation. They are actively involved in clinical trials exploring the efficacy of their lead compound, Chrysalin (TP508), for tissue repair and regenerative medicine.
Industries
Nr. of Employees
small (1-50)
Chrysalis BioTherapeutics
Products
Investigational regenerative thrombin‑derived peptide therapeutic (23‑amino‑acid peptide)
An investigational short peptide developed to stimulate endothelial and progenitor cell‑mediated tissue repair; evaluated preclinically and clinically for wound healing, musculoskeletal repair, ARDS, and radiation countermeasure indications.
Investigational regenerative thrombin‑derived peptide therapeutic (23‑amino‑acid peptide)
An investigational short peptide developed to stimulate endothelial and progenitor cell‑mediated tissue repair; evaluated preclinically and clinically for wound healing, musculoskeletal repair, ARDS, and radiation countermeasure indications.
Services
Preclinical efficacy and mechanism‑of‑action studies
Design and execution of in vitro and in vivo studies to evaluate efficacy, endothelial/vascular effects, and mechanisms of peptide therapeutics in radiation and lung injury models.
IND enabling, regulatory and GLP study management
Regulatory support, IND preparation, management of GLP/nonclinical studies and coordination with agencies for medical countermeasure and pulmonary indications.
CMC and clinical formulation development
Assay development, clinical formulation, and planning for large‑scale manufacturing to support clinical safety/PK and pivotal studies.
Collaborative government‑funded development programs
Partnerships and contract execution with federal agencies for development of therapeutics as medical countermeasures and for infectious/respiratory indications.
Clinical trial conduct and evidence generation for tissue repair
Design and conduct of early‑phase clinical trials (Phase I/II) for wound healing and tissue repair indications, including randomized placebo‑controlled study designs and clinical outcome assessments.
Preclinical efficacy and mechanism‑of‑action studies
Design and execution of in vitro and in vivo studies to evaluate efficacy, endothelial/vascular effects, and mechanisms of peptide therapeutics in radiation and lung injury models.
IND enabling, regulatory and GLP study management
Regulatory support, IND preparation, management of GLP/nonclinical studies and coordination with agencies for medical countermeasure and pulmonary indications.
CMC and clinical formulation development
Assay development, clinical formulation, and planning for large‑scale manufacturing to support clinical safety/PK and pivotal studies.
Collaborative government‑funded development programs
Partnerships and contract execution with federal agencies for development of therapeutics as medical countermeasures and for infectious/respiratory indications.
Clinical trial conduct and evidence generation for tissue repair
Design and conduct of early‑phase clinical trials (Phase I/II) for wound healing and tissue repair indications, including randomized placebo‑controlled study designs and clinical outcome assessments.
Expertise Areas
- Peptide therapeutic development
- Preclinical in vivo efficacy studies and animal model development
- Medical countermeasure development for radiation exposure
- Endothelial and vascular biology related to tissue repair
Key Technologies
- Thrombin‑derived peptide therapeutics
- In vivo radiation and ARDS animal models
- Endothelial function assays (NO production, tube formation, sprouting)
- DNA damage and repair assays (γ‑H2AX foci quantification)